RNTX

Rein Therapeutics Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.56

Price (1 Year)

$1.76 $0.56

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %9.1 / %30
Non-compliant assets / Total market cap %65.2 / %30
Non-compliant revenue / Total incomeNo data

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Website

Analysis (Turkish): RNTX Hissesi Caiz mi, Helal mi? Rein Therapeutics Inc. Katılım Analizi